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Abstract 
Therapeutic intra-articular injections are becoming an increasingly popular treatment 
modality for osteoarthritis, in particular in its initial stage. The available literature 
provides varied reports on the efficacy of drugs being administered directly into the 
joint cavity. This results from inconsistent research methods and assessment criteria. 
There is considerable controversy as to the best therapeutic approach in everyday 
clinical practice. The aim of this paper was to present synthetically information and 
research results concerning the use of selected therapeutic agents in intra-articular 
injection treatment. The collected data is supposed to facilitate adjusting treatment 
strategies to patients' individual needs. 
Keywords: intra-articular injections, synovial fluid, joint 
 
Introduction 
The technological leap at the turn of the 20th and 21st centuries and constant 
development of knowledge about the pathomechanisms of diseases allow more 
accurate management of sources of health problems. Currently, orthopaedists 
reduce the number of indications for systemic use of anti-inflammatory drugs. 
Patients are more often offered solutions such as intra-articular topical injections or 
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drugs to be administered directly in the area of bone and soft tissue damage. Intra-
articular injections are becoming increasingly popular nowadays. In terms of 
anticipated therapeutic results, we can distinguish diagnostic, decompressive and 
therapeutic intra-articular injections as well as compilations of the above mentioned 
types. 
Because of the issue’s complexity, in our report we focus on therapeutic injections. 
The major advantage of employing such way of treatment is a higher bioavailability of 
drugs at the spot of injection in comparison to their general application [1]. 
Anatomically, this results from the avascularity of articular cartilage, which 
significantly impairs a drug’s access to zones of damage [2]. The attempts to 
overcome this barrier involve long-term administration of high-dose drugs, which 
leads to an increased risk of systemic side effects, especially in case of chronic 
conditions. For this reason, intra-articular injections seem to be a safer treatment 
modality, which offers drug application in the proximity of damaged intra-articular 
structures [1]. There are many indications for therapeutic intra-articular injections, the 
most common of which include: traumatic or overload intra-articular injuries, 
degenerative and proliferative changes, inflammation of different aetiologies, 
haemorrhages, exudates or pain of unspecified aetiology [1, 3, 4, 5]. According to 
many authors, however, treatment with direct drug injections into the joint has 
multiple limitations. It should be remembered that intra-articular injections must not 
be carried out in the presence of uncontrolled coagulopathy, hypersensitivity to the 
active ingredient or during general or topical infection. [Błąd! Nie zdefiniowano 
zakładki.] Other absolute contraindications, which must not be ignored, are 
periarticular fractures and joint instability. [4] For an array of articular and general 
health problems there are no unambiguous safety criteria to perform therapeutic 
intra-articular injections. In the case of patients who are on anticoagulant therapy [5], 
have compromised blood coagulability for other pathological reasons [Błąd! Nie 
zdefiniowano zakładki.], are on immunosuppressive therapy [6] or suffer from 
diabetes [7], it has to be balanced if the advantages of the treatment outweigh the 
potential health risks. 
General principles of intra-articular injection treatment 
The decision to start treatment with therapeutic intra-articular injections must be 
based on a strong foundation of evidence-based medicine. After establishing 
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indications for such treatment, an appropriate drug should be chosen. The most 
commonly used agents include: hyaluronic acid and its derivates  [8, 9, 10], 
glucocorticosteroids [11, 12, 13, 14], platelet-rich plasma (PRP)  [15, 16, 17], 
collagen [18], radioactive isotopes [19, 20] and progenitor stem cells [21, 22]. The 
drug should be administered in a sterile environment [23]. Injections have to be done 
in accordance with current guidelines and the procedure can be guided by 
ultrasonography or fluoroscopy for considerably easier targeting [1]. Undoubtedly, the 
physician’s knowledge and experience are crucial during the procedure. For this 
reason, injections into the hip or spine should be done by the most qualified persons 
[Błąd! Nie zdefiniowano zakładki.]. In this paper, we intend to focus on three 
preparations which are most commonly used in intra-articular injection therapies: 
hyaluronic acid, glucocorticosteroids and platelet-rich plasma [24]. 
 
Hyaluronic acid 
Hyaluronic acid is one of a group of organic compounds called glycosaminoglycans. 
In the human body, it is the major component of the synovial fluid [25]. It exhibits 
hygroscopic properties and is the predominant component of the hyaline cartilage. 
Hyaluronic acid makes it possible for diffusion to satisfy the nutritional needs of the 
articular cartilage. It provides a mechanical barrier to protect the surface of the 
hyaline cartilage from excessive pressures during physiological joint loading. It also 
reduces friction and tangent forces to the articular surfaces between bones [26, 27]. 
Hyaluronic acid preparations and its derivates are injected transcutaneously into the 
joint cavity during early osteoarthritis to protect the cartilage from further deterioration 
[10]. As proven by experiments and everyday practice, they are safe and well 
tolerated by patients [28]. However, the disadvantages of this treatment modality 
include short duration of pain relief and no microscopically observed effect of articular 
cartilage regeneration. Concerning the high costs of such therapy, the results of 
treatment are disproportionately limited [5]. In 2015, a meeting of experts from 
different countries was organised to summarise the current state of knowledge and to 
adopt a position on viscosupplementation [10]. The indication for hyaluronic acid 
injections into the knee joint is pain in the course of mild to moderate degenerative 
and proliferative changes. It is not recommended using hyaluronic acid as a method 
of last resort. Drug injections cause a subjective decrease in pain and complement 
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nonsteroid anti-inflammatory therapies [10]. Clinical studies showed a major 
decrease in the analgesic efficacy  of hyaluronates as early as at six weeks after 
injection. However, some studies confirmed the positive anodyne effect as long as at 
26 weeks after injection [10]. The knee joint is most commonly accessed and treated 
through a lateral approach at the level of the base of the patella [10]. Experts did not 
confirm unambiguously the positive impact of hyaluronic acid in the treatment of 
glenohumeral joint arthritis. Unfortunately, the amount of workmanly research is small 
[29, 30]. The use of hyaluronic acid in patients with talocrural joint arthritis seems to 
be advantageous in treating early to moderate stages of the disease. In advanced 
arthritis, no positive impact on pain levels and inhibiting the progression of 
pathological changes was demonstrated [10]. In the affected hip joint, the application 
of hyaluronic acid can yield temporarily favourable outcomes, but only in the initial 
arthritis stage. In advanced forms of coxarthrosis, hyaluronates were not reported to 
have any therapeutic impact on pain intensity and disease progression [31]. Migliore 
et al. pointed out that ultrasound-guided injections provided a longer therapeutic 
effect [32]. 
Glucocorticosteroids 
Glucocorticosteroids are drugs with anti-inflammatory and immunosuppressive 
properties. They inhibit an inflammatory response, including joint inflammation, by 
using different mechanisms. As such they do not exhibit analgesic effects. They exert 
a systemic influence on protein and fat metabolism as well as affect the 
cardiovascular and central nervous systems. During treatment, it should be 
remembered that glucocorticosteroid interact with many drugs from different groups 
and cause multiple side-effects [33]. Knee joint injections may alleviate pain and 
increase joint mobility in chronic and acute osteoarthritis. Hepper et al. reported a 
positive effect of intra-articular knee steroid injections, but with short-term benefits of 
up to approximately 4 weeks [12]. Arden et al. showed a significantly longer duration 
of up to 26 weeks [13]. In their study published in 2012, Yavuz et al. demonstrated 
higher efficacy of methylprednisolone in comparison to betamethasone, with the 
treatment effect of both drugs being significantly smaller at 12 weeks after injection 
[14]. It is difficult to clearly define the duration of the analgesic effects of 
corticosteroid injections in the treatment of knee osteoarthritis. Frozen shoulder 
patients were reported to experience positive effects of treatment at one month after 
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intra-articular steroid injection [34]. An even more rapid response was observed in 
patients with arthritis of the first carpometacarpal joint. Positive effects of 
glucocorticosteroid treatment were evident as early as in the first weeks after 
injection and pain decreased in 68% of the examined patients during a two-year 
follow-up period [35]. Relatively long-term therapeutic effects were observed in hallux 
rigidus patients. In such cases, steroid injections were effective up to 3 months from 
the beginning of the treatment [36]. 
Platelet-rich plasma 
Biological treatment by using autologous growth factors has found its application in 
patients with intra-articular lesions. The most popular treatment option is the use of 
therapeutic intra-articular injections where preparations of autologous leukocyte- and 
platelet-rich plasma (L-PRP) are administered [15]. Platelet-rich plasma contains 
numerous growth factors and some other cytokines. They are released from platelets 
and may stimulate tissue repair processes [16]. An undeniable advantage of 
employing platelet-rich plasma is the simple, cheap and non-invasive way of applying 
large numbers of  autologous cells with healing mediators to the injured area. These 
substances also decrease pain and limit the intensity of inflammation. The clinical 
outcomes are promising and include pain alleviation, improved joint functionality and 
better life quality [37]. In clinical studies, it turned out that better results were obtained 
in young patients with early to moderate osteoarthritis [38]. Unfortunately, there is no 
reliable data to show if PRP causes osteophytes to regress or articular cartilage or 
other structures to regenerate. Although more level I and II evidence-based research 
into platelet preparations is needed, PRP appears to be a validated treatment 
modality for early to moderate joint osteoarthritis because it is simple to obtain, cheap 
and widely available and its efficacy was confirmed by encouraging preliminary 
results [39]. Promising results were published in 2010 by Kon et al. In their study, 115 
patients were treated with PRP for gonarthrosis. At 6 and 12 months, a crucial 
improvement was achieved when compared to the control group [17]. In 2011, 
Filardo et al. analysed a similar-sized group, but with a longer follow-up period of 2 
years. There was no doubt that the positive therapeutic effect of PRP decreased 
during the follow-up, but it was still significantly higher than in the placebo group [40]. 
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Discussion 
In 2014, Ayhan et al. collected and summarized the available information on  
therapeutic knee joint injections [24]. Hyaluronic acid and glucocorticoids injections 
provided similar clinical effects up to 4 weeks, but after that period hyaluronic acid 
proved more effective in reducing pain and joint stiffness [28, 41]. Therapies with 
platelet-rich plasma and hyaluronic acid were compared in a total of 150 patients and 
it turned out that PRP patients obtained better results in reducing pain and joint 
stiffness up to 6 months after injection. Furthermore, differences in favour of PRP 
were significant in young patients with chondromalacia or early osteoarthritis [42]. No 
significant differences in the efficacy of PRP and hyaluronic acid treatment were 
recorded in advanced osteoarthritis patients over 50 years of age [43, 44]. It is 
recommended that glucocorticosteroid therapy be used for the shortest time possible. 
However, where surgery is contraindicated, steroid intra-articular injections seem to 
be justified in acute or chronic synovitis unless they are carried out immediately 
before surgical treatment [24]. Hyaluronic acid injections are most commonly 
performed in patients above 60 years of age who do not accept surgical treatment 
[24]. Autologous platelet-rich plasma appears to be the best treatment option in 
patients under 60 years of age with mild osteoarthritis and a BMI under 30. Patients 
above 60 years of age with moderate arthritis or a BMI above 30 can still be treated 
with PRP, but it is recommended that a supplementary hyaluronic acid injection be 
performed at 2 to 4 weeks afterwards [24]. 
Summary 
As medicine develops and new therapies arise, the available treatment algorithms 
require frequent adjustments to include valuable reports and clinical studies. 
Physicians should not depend only on their own experience and limit themselves to 
previously known treatment methods. On the contrary, they are obliged to analyse 
and introduce systematically newer methods to prevent or manage changes caused 
by body wear, such as degenerative diseases. This is possible only after a thorough 
analysis of the literature. Intra-articular injections are becoming increasingly common 
and every physician should know the main advantages and disadvantages of this 
treatment modality. According to many authors, therapeutic intra-articular injections 
are very useful in inhibiting the progression of degenerative disease and improving 
the quality of live [Błąd! Nie zdefiniowano zakładki., Błąd! Nie zdefiniowano 
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zakładki., Błąd! Nie zdefiniowano zakładki., Błąd! Nie zdefiniowano zakładki., 
Błąd! Nie zdefiniowano zakładki., Błąd! Nie zdefiniowano zakładki., Błąd! Nie 
zdefiniowano zakładki., Błąd! Nie zdefiniowano zakładki.]. However, further 
research is needed to develop the best criteria that may be used to triage patients to 
different forms of intra-articular injections. 
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